BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BC Innovations | Aug 1, 2019
Product Development

NeuBase takes antisense oligos to more targets in more places

Newcomer NeuBase Therapeutics is re-engineering antisense oligos to access a broader range of targets, while simultaneously solving the modality’s dosing and delivery issues. With three approvals since the start of 2016, antisense oligonucleotides (ASOs) have...
BC Extra | May 17, 2019
Financial News

Actuate gets $21.7M to expand clinical testing of lead candidate

With its $21.7 million series B round, Actuate plans to expand clinical testing of its GSK3B inhibitor into Europe and advance its pediatric neuroblastoma program for the candidate. Kairos Ventures led the round, with participation...
BC Innovations | May 14, 2019
Distillery Therapeutics

GSK3A inhibition restores asparaginase sensitivity in resistant ALL, AML

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting GSK3A could help treat asparaginase-resistant T cell and B cell ALL and AML. In a T...
BC Innovations | Mar 5, 2019
Distillery Techniques

Vascularized kidney organoids for modeling renal disease

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: 3-D models Vascularized kidney organoids could be used to study kidney development and model renal diseases. The organoids are generated in three steps: culturing human pluripotent stem cells with fibroblast...
BC Innovations | Dec 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; colorectal cancer; lung cancer Cell culture and mouse studies suggest inhibiting GSK3 could help treat KRAS-driven pancreatic, colon and lung cancers. Screening of a library of 304 kinase inhibitors in cell-based growth...
BC Innovations | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
BC Innovations | Oct 18, 2018
Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Rat studies suggest human embryonic stem cell (hESC)-derived spinal cord neural stem cells (NSCs) could help treat SCI. hESCs were cultured with fibroblast growth factors and inhibitors of bone morphogenic...
BC Innovations | Aug 23, 2018
Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and cell culture studies identified two thiazolidinedione-based dual inhibitors of tau-aggregation and GSK3B that could help treat AD. Chemical synthesis and in vitro testing in enzymatic activity assays of...
BC Innovations | May 16, 2018
Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Patient sample and mouse studies suggest inhibiting GSK3B could help treat Rett syndrome. In postmortem cerebellum tissue samples from Rett syndrome patients, levels of GSK3B were higher than in samples from unaffected...
Items per page:
1 - 10 of 99